title: [Type 2 diabetes complications].
abstract: People with type 2 diabetes are at increased risk of many complications, which are mainly due to complex and interconnected mechanisms such as hyperglycemia, insulino-resistance, low-grade inflammation and accelerated atherogenesis. Cardi-cerebrovascular disease are frequently associated to type 2 diabetes and may become life threatening, particularly coronaropathy, stroke and heart failure. Their clinical picture are sometimes atypical and silencious for a long time. Type 2 diabetes must be considered as an independent cardiovascular risk factor. Nephropathy is frequent in type 2 diabetes but has a mixed origin. Now it is the highest cause of end-stage renal disease. Better metabolic and blood pressure control and an improved management of microalbuminuria are able to slowdown the course of the disease. Retinopathy which is paradoxically slightly progressive must however be screened and treated in these rather old patients which are globally at high ophthalmologic risk. Diabetic foot is a severe complication secondary to microangiopathy, microangiopathy and neuropathy. It may be considered as a super-complication of several complications. Its screening must be done on a routine basis. Some cancer may be considered as an emerging complication of type 2 diabetes as well as cognitive decline, sleep apnea syndrome, mood disorders and bone metabolism impairments. Most of the type 2 diabetes complications may be prevented by a strategy combining a systematic screening and multi-interventional therapies.
authors.affiliation: Faculté de médecine Strasbourg, 67200 Strasbourg, France. jean-louis.schlienger@wanadoo.fr
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Schlienger
mesh_terms: D001847:Bone Diseases / Q000209:etiology; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D003072:Cognition Disorders / Q000209:etiology; D016207:Cytokines / Q000502:physiology; D003866:Depressive Disorder / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000209:etiology / Q000503:physiopathology; D017719:Diabetic Foot / Q000209:etiology / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D003929:Diabetic Neuropathies / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D004198:Disease Susceptibility; D006801:Humans; D007239:Infections / Q000209:etiology; D007249:Inflammation / Q000209:etiology / Q000503:physiopathology; D009369:Neoplasms / Q000209:etiology; D012891:Sleep Apnea Syndromes / Q000209:etiology
chemical_list: D016207:Cytokines